These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34382352)

  • 1. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
    Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
    Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
    Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
    Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
    Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
    BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
    Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
    Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Ito T; Kanao K; Takahara K; Ando R; Yasui T; Shiroki R; Sumitomo M; Miyake H
    Anticancer Res; 2019 Jun; 39(6):3089-3094. PubMed ID: 31177153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
    Fujiwara M; Yuasa T; Yasuoka S; Komai Y; Oguchi T; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):525-531. PubMed ID: 34110449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
    Kim KB; Jo JK; Ahn S; Lee S; Jeong SJ; Hong SK; Byun SS; Lee SE
    Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.